Patents for A61P 35 - Antineoplastic agents (221,099)
06/2011
06/16/2011WO2011070024A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use
06/16/2011WO2011069962A1 Bibw 2992 for use in the treatment of triple negative breast cancer
06/16/2011WO2011069916A1 Triazole compounds, use thereof as a fungicide, and agents comprising same
06/16/2011WO2011069799A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069798A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069797A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069796A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069795A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069794A1 Neutralizing prolactin receptor antibodies and their therapeutic use
06/16/2011WO2011069761A1 Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
06/16/2011WO2011069336A1 Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
06/16/2011WO2011069335A1 Use of pyridines compounds in preparing rna interference reinforcing agent
06/16/2011WO2011069334A1 Cdk5 inhibitors and therapeutic uses thereof
06/16/2011WO2011047770A3 Pyrazolopyrimidine derivatives
06/16/2011WO2011041731A3 Method of inhibiting bcl-2-related survival proteins
06/16/2011WO2011039735A3 Compounds with ddx3 inhibitory activity and uses thereof
06/16/2011WO2011031474A3 Use of metformin in cancer treatment and prevention
06/16/2011WO2011029028A9 Targeted delivery using tissue-specific peptidomimetic ligands
06/16/2011WO2011025167A3 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof
06/16/2011WO2011022694A3 Furanopyrimidine cannabinoid compounds and related methods of use
06/16/2011WO2011022692A3 Furanopyridine cannabinoid compounds and related methods of use
06/16/2011WO2011022679A3 Benzofuran cannabinoid compounds and related methods of use
06/16/2011WO2011022509A3 Substituted benzoazepines as toll-like receptor modulators
06/16/2011WO2011022489A3 (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
06/16/2011WO2011022056A3 PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF
06/16/2011WO2011019393A3 Class- and isoform-specific hdac inhibitors and uses thereof
06/16/2011WO2011017162A9 Methods for enhancing antigen-specific immune responses
06/16/2011WO2011017143A3 Compositions and methods of preparing alloreactive cytotoxic t cells
06/16/2011WO2011017107A3 Microbubble assisted viral delivery
06/16/2011WO2011017096A3 Methods of treating hematologic cancers
06/16/2011WO2011014825A3 Antiangiogenic small molecules and methods of use
06/16/2011WO2010149357A3 Methods of using corticotropin-releasing factor for the treatment of cancer
06/16/2011WO2010139942A3 Nanoparticle for biomolecule delivery
06/16/2011WO2010121576A3 Novel 7-deazapurine nucleosides for therapeutic uses
06/16/2011WO2009132234A3 Medical devices, polymers, compositions, and methods for delivering a haloacetate
06/16/2011US20110145941 Antibodies and derivatives thereof
06/16/2011US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products
06/16/2011US20110144212 Key intermediate for the preparation of stilbenes, solid forms of pterostilbene, and methods for making the same
06/16/2011US20110144209 Use of vasoconstrictors
06/16/2011US20110144206 Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity
06/16/2011US20110144202 Concentrated oxaliplatin solution and its method of preparation
06/16/2011US20110144198 Breast cancer prognostics
06/16/2011US20110144186 Ssx-2 peptides presented by hla class ii molecules
06/16/2011US20110144185 Rna antagonists targeting hsp27
06/16/2011US20110144183 Oligonucleotides for treating inflammation and neoplastic cell proliferation
06/16/2011US20110144163 Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents
06/16/2011US20110144161 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
06/16/2011US20110144158 Isoindole-imide compounds and compositions comprising and methods of using the same
06/16/2011US20110144156 A3 adenosine receptor allosteric modulators
06/16/2011US20110144155 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
06/16/2011US20110144147 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
06/16/2011US20110144143 pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof
06/16/2011US20110144139 Hepsin inhibitors
06/16/2011US20110144138 Substituted pyrimido isoquinoline derivatives
06/16/2011US20110144134 Anti-Inflammatory Pyrazolopyrimndines
06/16/2011US20110144132 Substituted pyrimidin-4-one derivatives
06/16/2011US20110144126 Compounds useful for inhibiting chk1
06/16/2011US20110144123 Thiazoles and Oxazoles Useful as Modulators of ATP-Binding Cassette Transporters
06/16/2011US20110144122 Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
06/16/2011US20110144116 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS
06/16/2011US20110144115 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
06/16/2011US20110144114 Substituted triazinone derivatives
06/16/2011US20110144113 Triazolotriazines as kinase inhibitors
06/16/2011US20110144110 Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents
06/16/2011US20110144103 Pyrrole compounds that modulate hsp90 activity
06/16/2011US20110144101 Macrocyclic compounds useful as pharmaceuticals
06/16/2011US20110144100 Triazolopyridine compounds as pim kinase inhibitors
06/16/2011US20110144099 Aryloxy and arylalkyleneoxy substituted imidazoquinolines
06/16/2011US20110144097 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazin-4-yl)-phenyl]-amides
06/16/2011US20110144092 Substituted alkyl pyrimidin-4-one derivatives
06/16/2011US20110144085 Triazolopyridine compounds as pim kinase inhibitors
06/16/2011US20110144084 6 substituted 2- heterocyclylamino pyrazine compounds as chk-1 inhibitors
06/16/2011US20110144080 Pyrazole derivatives as protein kinase modulators
06/16/2011US20110144074 Caspase inhibitors and uses thereof
06/16/2011US20110144068 3,4-diarylpyrazoles as protein kinase inhibitors
06/16/2011US20110144066 Small molecule inhibitors of the pleckstrin homology domain and methods for using same
06/16/2011US20110144065 Selective high-affinity polydentate ligands and methods of making such
06/16/2011US20110144047 Combined method for predicting the response to an anti-cancer therapy
06/16/2011US20110144043 Stat modulators
06/16/2011US20110144042 Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative
06/16/2011US20110144039 Antioxidative and hepatoprotective compositions containing diaryheptanoids from alnus japonica
06/16/2011US20110144037 Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use
06/16/2011US20110144034 Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
06/16/2011US20110144033 Proteasome Inhibitors and Methods of Using the Same
06/16/2011US20110144032 Biological applications of steroid binding domains
06/16/2011US20110144031 Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same
06/16/2011US20110144023 Nano Cancer Barrier Device (NCBD) to Immobilize and Inhibit the Division of Metastic Cancer Stem Cells
06/16/2011US20110144016 Methods and Compositions for Treating Cancer
06/16/2011US20110144015 Methods for treating muscle diseases and disorders
06/16/2011US20110144014 Cytokine receptor modulators and uses thereof
06/16/2011US20110144007 Glucose-dependent insulinotropic polypeptide analogues
06/16/2011US20110144004 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
06/16/2011US20110143993 Endothelial basement membrane targeting peptide ligands
06/16/2011US20110143992 Methods and Compositions Related to GHS-R Antagonists
06/16/2011US20110143991 Peptides for Activation and Inhibition of Delta-PKC
06/16/2011US20110142969 Extract of piper betel leaves for the treatment of human malignancies by inducing oxidative stress
06/16/2011US20110142963 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
06/16/2011US20110142961 Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients
06/16/2011US20110142950 Polymer micelles containing anthracylines for the treatment of cancer
06/16/2011US20110142948 Nanoparticle Carrier Systems based on Human Serum Albumin for Photodynamic Therapy